Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Colorectal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Saurav Haldar, MD) · GIClinicalTrials@mdanderson.org · 713-792-5111
Contact: Principal Investigator (Saurav Haldar, MD)

Study leads

Saurav Haldar, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)

Abroad (travel likely)RecruitingPHASE3

Mobile, United States · Tuscaloosa, United States

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Metastatic Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

New Haven, United States · Grand Rapids, United States

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Colorectal Cancer Metastatic · Liver Metastases · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE2

New York, United States

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Pancreatic Ductal Adenocarcinoma · Non Small Cell Lung Cancer · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Los Angeles, United States · Baltimore, United States